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30 Years of Neuroendocrinology: technological advances 
pave the way for molecular discovery 
Felicity E. Stubbs, Becky L. Conway-Campbell and Stafford L. Lightman 
 
   Since the 1950’s (1) the systems level interactions between the hypothalamus, pituitary and 
end organs such as the adrenal, thyroid and gonads have been well known, however it is only 
over the last three decades that advances in molecular biology and information technology 
have provided a tremendous expansion of knowledge at the molecular level. 
Neuroendocrinology has benefitted from developments in molecular genetics, epigenetics 
and epigenomics, and most recently optogenetics and pharmacogenetics. This has enabled a 
new understanding of gene regulation, transcription, translation and post-translational 
regulation, which should help direct the development of drugs to treat neuroendocrine 
related diseases.  
   Understanding the molecular mechanisms of steroid receptor signalling is a very important 
aspect of gaining information about the underlying causes of diseases associated with 
aberrant signalling, such as in hormone sensitive cancers or the side-effects of steroid 
treatment. One of the most important neuroendocrine systems is the hypothalamic-pituitary-
adrenal axis, which regulates the release of glucocorticoid hormones from the adrenal glands 
and is critical for the maintenance of homeostasis.  Glucocorticoids are clinically widely used 
due to their potent anti-inflammatory effects. Prolonged use of high doses of glucocorticoids 
is associated with many unwanted side-effects and often therapy is complicated by the 
development of glucocorticoid resistance. A better understanding of the molecular 
mechanisms of glucocorticoid receptor (GR) signalling will provide the rationale for better  
therapy, as well as limiting adverse side-effects and the development of resistance. Similarly, 
understanding the molecular mechanisms of intracellular receptors for estrogen (ER), 
progesterone (PR) and androgen (AR) may aid in the development of more specific therapies 
for diseases such as breast cancer or prostate cancer respectively, where dysregulation of 
signalling can promote disease development and progression.  The importance of this was 
recognised 30 years ago when the journal of Neuroendocrinology was established! 
     The human genome project has enabled scientists to examine the entire complement of 
human genes, as well as their RNA and protein expression, instead of the conventional time-
consuming methods focusing on individual components. The development of more advanced 
ways to assess chromatin structure and interactions such as receptor binding is enhancing our 
knowledge of these cellular processes as well as providing a new understanding of the 
dynamics of how hormone receptors interact with the chromatin landscape. In addition to 
this, new ways to edit the genome such as CRISPR, have become powerful tools in assessing 
the function of proteins. Optogenetics and Pharmacogenetics are also helping determine the 
specific roles of subsets of neurons as well as identifying neuron circuitry. Together these 
techniques have begun to enable molecular biology to advance the practice of medicine by 
determining the molecular alterations which promote disease, thereby leading to the future 
design of specific, more targeted treatments.  
 
High throughput sequencing and steroid receptor action  
   High throughput sequencing techniques have become a major tool for the identification of 
molecular mechanisms across many scientific fields. Previously RNA analysis was restricted to 
analysis of known transcripts while modern sequencing enables analysis on a genome-wide 
scale requiring no prior knowledge of which genes are expressed. Many now believe RNA-Seq 
to be a more sensitive technique allowing more accurate measurements of transcript levels 
(2, 3). Despite some controversy, it is clear this technique can form a basis for most studies 
and unveil potential directions which can be further explored using the conventional 
techniques including microarrays and real-time quantitative polymerase chain reaction 
(qPCR). RNA-Seq is proving useful in characterizing differences in gene expression between 
specific cell types and in determining the changes which exist promoting glucocorticoid 
resistance (4-6). It has for instance recently been used to show how cyclosporine A, a drug 
frequently used to rescue glucocorticoid resistant diseases, can promote a genome-wide shift 
attenuating the responsiveness of a cell line prone to promoting resistance (4). This is 
important as patients which become glucocorticoid resistant often require high doses leading 
to several side effects. Understanding the biological mechanisms that cause resistance may 
help identify other therapies to aid glucocorticoid treatment of these patients in the future. 
Similarly, RNA-Seq is helping identify gene expression changes in response to estrogen, 
progesterone and androgens across different types of cancers (7-10) and has been used as an 
unbiased tool for transcriptome analysis in MCF7 breast cancer cells to determine ER 
regulatory pathways (7). Advanced analysis techniques are also enabling hierarchical 
clustering of genes according to hormone-dependent expression patterns, such as SupraHex 
analysis (5, 11), and functional pathway analyses providing detailed information about the 
genome-wide expression profiles of individual cells. Another advantage of RNA-Seq is that it 
can be used to identify splice variants and mutations such as short nucleotide polymorphisms 
(SNPs). In a study using palmitate treated human islets of Langerhans, more than 3000 splice 
variants that had not been detected in previous microarray studies were identified (12). 
Advances in information technology combined with accurate mapping of RNA-Seq reads (13, 
14) has aided the identification of SNPs in diseases such as cancer (15, 16). In addition to RNA-
Seq, a technique referred to as ‘Drop-seq’ analyses mRNA transcripts from individual cells and 
determines the transcripts’ cell of origin, which is incredibly useful for expression profiling of 
heterogenous cell populations in-vivo. In mouse retinal tissue, 39 transcriptionally unique cell 
populations were found from over 40000 cells (17). This shows how large-scale single cell 
analysis can help improve our understanding of individual cell populations in complex neural 
tissue.  
  Advances in protein sequencing techniques using mass spectrometry have aided the 
examination of global protein expression. This is improving our understanding of the 
processes occurring from hormone-mediated transcriptional expression to translation. It is 
also enabling scientists to identify the proteins present in individual cell types and determine 
interactions between proteins using coimmunoprecipitation techniques. By comparing 
protein expression in disease state to a control, this enables determination of which proteins 
gain or lose expression or interactions with other proteins, for example in cancer due to 
specific mutations. Using liquid chromatography mass spectrometry (LC-MS) proteomics has 
identified differences in proteins present in androgen-dependent and independent cancer 
cells compared to normal prostate epithelium (18). Proteins interacting with ERalpha have 
been determined using LC-MS in human breast cancer (19). This technique can thereby hasten 
the identification of novel drug targets. 
 
Steroid receptor binding and chromatin accessibility  
  Understanding the chromatin landscape can help inform us of the genomic response of 
transcription factors by determining transcription factor binding as well as predicting 
regulatory regions by assessing chromatin accessibility, nucleosome mapping and dynamic 
long-distance chromatin conformations, including looping. The first studies to suggest nuclear 
hormone receptor interactions with chromatin appeared as early as the 1960s (20-22). 
However direct evidence for this came later and was first reported using binding assays. Since 
then, chromatin immunoprecipitation (ChIP) developed in the 1990s, has become a widely 
used technique for assessing protein-DNA interactions. This technique has greatly advanced 
our understanding of the binding of nuclear receptors, co-factors, and other components of 
the transcriptional machinery such as Polymerase II, to specific DNA regulatory sites of a few 
well-known candidate genes. ChIP has been used to assess time-dependent transcription 
factor binding in live cells and in-vivo due to its ability to fix proteins at any point in time. Early 
studies by Chen and colleagues (23), demonstrated recruitment of ER as well as co-factors to 
target genes following treatment with estradiol in MCF7 cells. Here, they showed that 
although ER binding remained, time dependent changes in recruitment of co-factors such as 
acetyltransferases CBP and p300 unexpectedly correlated to a decrease in transcription of c-
Myc and cathepsin D (CTD). This study and similar more recent studies (24-27), have 
demonstrated the sequential recruitment of co-factors including histone acetyltransferases, 
histone methyltransferases and subunits of the chromatin remodelling BRG1 associated 
factor (BAF) complex to promote transcription. The advance of ChIP sequencing (ChIP-Seq) 
has allowed us to identify genome-wide binding sites for transcription factors such as GR. 
Figure 1 shows ChIP-Seq data from rat hippocampal tissue, highlighting a selection of GR 
binding events induced by acute stress and exogenous corticosterone treatment (28).  
    Additionally, ChIP-Seq has enabled the genome-wide assessment of how binding profiles 
for GR, ER, PR and AR are highly cell-type specific and subject to alteration with changing 
environmental conditions (29-36) as well as being dependent upon other regulatory proteins 
such as AP-1 and Foxa1 (30, 37). ChIP-Seq has revealed insights into loss of protein-DNA 
associations occurring in disease states, such as cancer, increasing our understanding of 
disease development and potentially leading to the development of more specific therapies. 
Recently advances in ChIP protocols has seen the development of a robust ChIP-exo 
technique referred to as ChIP-nexus which uses an exonuclease for high nucleotide resolution 
and an additional DNA self-circularization step during library preparation (38). This produces 
high quality data with high resolution at the single nucleotide level (38). Future studies are 
already focusing on improving the ChIP technique further using UV Laser ChIP-Seq (39) to 
improve the identification of proteins that are in immediate contact with nucleic acids rather 
than being tethered to other proteins.  
    Other studies have focused on the interactions of steroid receptors and alterations in the 
chromatin architecture. For GR, early studies have involved the extensive use of the MMTV 
promoter as a model system (40-43). The advance of DNase I techniques to assess chromatin 
accessibility also showed GR to induce ‘de novo’ chromatin remodelling of the MMTV array 
by interactions with the SWI/SNF complex (44-46). DNase I cuts regions of more open chro-
matin which result from changes in nucleosome structure (47, 48). The combination of ChIP 
and DNase I studies with sequencing has recently become a powerful tool. DNase I sequencing 
again is a genome-wide approach and requires no previous knowledge of the sequence or the 
protein of interest (49). Alongside this has been the development of Formaldehyde-Assisted 
Isolation of Regulatory Elements sequencing (FAIRE-Seq) to assess open chromatin and nu-
cleosome occupancy (50), micrococcal nuclease sequencing (MNase-Seq) (51, 52) to deter-
mine nucleosome positions, and most recently ATAC-Seq (Assay for Transposase-Accessi-
ble Chromatin using sequencing) (Figure 2). ATAC-Seq uses hyperactive Tn5 transposase to 
catalyse the movement of transposans to assess chromatin accessibility (53, 54). Tn5 cuts and 
inserts sequencing adaptors to open chromatin sites which can then be directly sequenced 
(55). This method is now seen as a quicker and more sensitive alternative to DNase-Seq for 
assessing chromatin accessibility and an alternative to MNase-Seq for assessing nucleosome 
positions (37, 56). These techniques have been important in determining the fundamentals 
of steroid receptor binding in combination with chromatin organisation, unveiling the com-
plex dynamics of steroid receptor mediated transcription. For example, before recent studies 
revealing nuclear receptors can bind at a great distance from target genes (57-59) it was be-
lieved that regulatory regions were confined to the proximal promoter region. In mouse 3134 
cells it has been observed that 93% of GR binding sites occur more than 2.5kb distal to the 
Transcription start site (TSS) (49). Using transcriptome profiling with GR ChIP-Seq, Uhlenhaut 
et al. (32) showed that less than 6% of GR binding sites occurred at proximal promoters in 
lipopolysaccharide activated macrophages. In HeLa cells it has also been demonstrated that 
24% of GR binding sites are > 25kb from the TSS with only 7% of binding sites located in the 
promoter region (60). Similarly, in rat hippocampal tissue few GR binding sites have been 
found in promoter regions (28, 61). In MCF7 cells, the majority of ER binding has also been 
shown to occur at great distances from TSS (34, 57). This has promoted suggestions of com-
plex chromatin looping to enable interactions between receptors and other transcriptional 
co-factors to promote transcription (34, 62).  
     These techniques have been key in elucidating the roles of steroid receptor-mediated 
transcription. In addition to this they have also revealed the complexity of chromatin 
organisation around regulatory sites, including identiﬁcation of epigenetic marks and the 
characteristics of inducible and repressible chromatin configurations. This aids our 
understanding of not only how transcription factors, regulatory complexes and proteins 
interact at the chromatin level but also how the dynamic chromatin structure is important for 
aiding interactions between proteins, for example by looping, to regulate a transcriptional 
response. Future applications of sequencing data combined with predictive modelling 
techniques may even form a basis for further investigations into how this chromatin structure 
aids regulation.  
 
Advances in Fluorescent In-situ Hybridisation (FISH) techniques 
  FISH uses probes consisting of nucleotide sequences incorporated with fluorophores to 
recognise the presence of complementary sequences in RNA or DNA. This technique which 
started being used in the 1980s has now been widely used to determine the genetic content 
and RNA expression of individual cells. RNA ISH (in situ hybridisation) enabled analysis of RNA 
using conventional brightfield or standard fluorescence microscopes but lacked sensitivity 
and specificity to accurately visualise single molecules. Recently RNAscope®, a novel 
multiplex RNA ISH technology, which uses unique probes to promote simultaneous signal 
amplification with low background, represents a major advance allowing more specific 
visualisation of gene expression in complex tissues (64). Another major advantage of the 
system is detection of low abundance mRNA expression. Therefore, for neuroendocrinology, 
this technique could enable us to co-localise hormone-dependent transcriptional responses 
with neurotransmitter and/or receptor mRNA distribution in a wide range of tissues. Figure 3 
shows the heterogenous distribution of mRNA expression of GR and MR, along with co-
localization to the glucocorticoid-target transcript Per1 in the dentate gyrus of the rat 
hippocampus. This increased resolution to the cellular level overcomes previous limitations 
associated with analysing heterogenous transcription in different cell types within the 
complex architecture of brain tissue.   
  A further example of this includes the Angiotensin receptor mRNA, which has recently been 
visualised in the paraventricular nucleus of the hypothalamus on corticotrophin releasing 
hormone (CRH) neurons enabling studies assessing correlations between loss of these 
receptors and levels of CRH mRNA (65-67). 
   Gene transcription has also been shown to occur in bursts with refractory periods (68-72) 
and single molecule RNA ISH (73, 74) can be used to study transcriptional bursts. By 
determining the frequency and size of these bursts (quantity of RNA produced) this 
technology can provide information into gene regulation in response to hormones in different 
brain regions. Visualisation of RNA in living cells is a further challenge crucial for obtaining 
important spatial and temporal data about RNA expression, localisation and storage. New 
techniques are now focused on tracking RNA in living cells and we may see a major advance 
in this over the next decade (75, 76). 
   Another advance in FISH techniques is the use of 3D DNA FISH to assess chromatin 
reorganisation in response to hormone receptor action. Jubb and colleagues (77) used 3D 
DNA FISH to assess glucocorticoid mediated chromatin decompaction at several loci. This 
provides extra information about speed and duration of chromatin decompaction which is 
difficult to determine using DNase I or ATAC-Seq techniques. This technique may similarly be 
used to investigate other hormone inducible changes in chromatin organisation during acute-
phase transcriptional regulation.  
 
Editing the genome to determine a functional role 
  The introduction of CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats)/Cas9 system has greatly advanced genome editing/engineering. CRISPR genome 
editing uses a system found in the prokaryotic immune system which introduces double 
strand breaks on viral DNA as a defence mechanism (78). A single guide RNA, complementary 
to the viral DNA sequence, directs Cas9 nuclease towards the viral DNA where it promotes a 
double strand break. This technology has been adapted and can be used to introduce 
mutations at specific sites in the genome.  In 2013 the system was first used for multiplex 
engineering in eukaryotic cells (79) and has rapidly become a widely used genome editing 
tool. CRISPR has already been used to introduce mutations into ERs (80, 81) to determine the 
importance of these mutations in endocrine resistance. Combined with RNA-Seq and ChIP-
Seq a single mutation Y537S in ER has been shown to promote constitutive ER activity 
promoting estrogen independent growth (81). This use of CRISPR demonstrates how it can be 
used to help identify what outcomes certain mutations can cause. CRISPR editing to disrupt 
AR has been shown to inhibit the growth of androgen sensitive prostate cancer cells (82). This 
could suggest another important use of CRISPR as a therapeutic target for prostate cancer. 
CRISPR editing of the PR has recently questioned the importance of PR in the role of female 
reproductive cyclicity in rodents (83) which remained despite other expected outcomes of PR 
deletion. This shows how CRISPR can be used to further decipher the roles of hormone 
receptors. Overall CRISPR is a powerful tool for introducing or editing mutations to further 
understand the roles of genes and known mutations in neuroendocrine disease.   
 
Optogenetic and Chemogenetic tools 
   The recent advances in optogenetics and chemogenetics is now enabling neuroscientists to 
modulate the activity of specific subsets of neurons using light or designer drugs. These are 
useful tools for helping functionally dissect which cells are important for specific roles, for 
example which subset of cells specify certain behaviours, emotions or are specific to certain 
motor functions. Optogenetics use Opsin-based receptors which are selectively expressed in 
cells of interest. The most frequent receptor used is channelrhodopsin which can be 
expressed in specific cell phenotypes. In-vivo, viruses can be used to deliver Cre dependent 
receptors to transgenic Cre-driver rodent lines (84). In neuroendocrinology, optogenetics has 
been valuable in determining control of pituitary hormone secretion (84). Gonadotropin 
releasing hormone (GnRH) neurons expressing channelrhodopsin have been used to show 
pulsatile release of luteinising hormone (LH) (85). Optogenetics has contributed to further 
understanding of important neural networks including those involved in homeostasis as well 
as for higher cognitive functions and emotional behaviours (86).  
   Pharmacogenetics, similarly to optogenetics, looks at variation in gene responses to 
stimulation of receptors, but by using pharmacological agents. This often begins with the 
discovery of an unexpected response to a drug and then looks at the genetic cause often by 
introducing selected genes to specific brain targets to alter cell function. An example of this 
is the treatment of Parkinson’s symptoms, usually treated with dopamine agonists, in rats by 
increasing GABA concentrations in the subthalamic nucleus by transferring the gene for 
gamma-amino butryic acid (GAD) which is the rate limiting enzyme in GABA production (87). 
Clinical trials on patients have since been trialled (88, 89). 
   More recently a new chemogenetic approach to studying specific cell populations utilizes 
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and is termed 
‘pharmacosynthetics’. DREADDs involve the use of receptor proteins designed through 
mutagenesis of endogenous G protein coupled receptor DNA. These ‘Designer Receptors’ can 
be targeted to specific neuronal subtypes by engineering to cell-specific endogenous 
promoter sequences, ensuring that only the specific neuronal population will be stimulated 
by the ‘Designer Drug’ clozapine-n-oxide (CNO). The specificity of DREADDs can be seen in the 
elegant studies of Yoshimura et al. (90) using the AVP-hM3Dq-mCherry transgenic rat. In 
Figure 4, acute systemic CNO treatment results in highly specific c-fos induction, indicating 
neuronal activation (91), within vasopressin neurons (hM3Dq-mCherry positive, AVP positive) 
in the supraoptic (SON) and the paraventricular nuclei (PVN). DREADDs can also be inhibitory 
when hM4Di (92-94), a variant of the endogenous M4 muscarinic acetylcholine receptor, is 
utilized.  DREADDs technology has been suggested to have several therapeutic applications, 
these include metabolic disorders (95), diabetes (96), depression and stress disorders (94, 97) 
and inflammatory disorders (98). For Parkinson’s disease, pharmacogenetics could re-
engineer neurons to produce neuroprotective neurotrophins to protect dopaminergic cells 
while optogenetics could promote cell type specific control for repair of dysfunction (99). 
 
 
Insight to the future 
   Recent technological advances in the field of quantitative fluorescence microscopy are 
allowing new insight into the biological activities taking place inside living cells. It is now 
possible to track individual proteins enabling scientists to obtain information such as 
transcription factor binding times and dissociation rates. GR has already been viewed in this 
way, labelled with a new generation of fluorescent tags with increased brightness and better 
photostability to aid visualisation at the single molecule level (100). This technology is only 
getting started but may very soon increase our understanding of the dynamics of how 
transcription factors such as GR interact with the chromatin landscape to promote 
transcription. This could promote a further expansion of our knowledge of molecular 
processes in living cells, potentially confirming previous findings and revealing a new 
understanding of dynamic cellular processes. In addition to this a surge in molecular data has 
also enabled an advance in mathematical modelling in the field of neuroendocrinology, to 
help us predict dynamic interactions of different proteins. Mathematical modelling can 
provide clues to what may be occurring in live cells based on previously acquired knowledge 
and may help direct future experiments and technology to further improve our molecular 
understanding. Combining these advances in single molecule tracking and mathematical 
modelling with further improvements to ChIP, chromatin accessibility, CRISPR and 
pharmacogenetics, the next 30 years will likely again see another explosion in molecular data 
and further advance our understanding of hormone regulation. 
 
Summary 
   The recent advance in sequencing techniques and the application of next generation 
sequencing to RNA, ChIP, DNase I, ATAC, MNase and FAIRE studies has revealed new insights 
into gene regulation in neuroendocrine systems. This enhances our understanding of 
biological pathways and importantly can identify events that have a role in causing various 
diseases, such as the development and progression of certain cancers. The introduction of 
CRISPR as well as similar genome editing techniques now enables scientists to study known 
mutations to model diseases, promoting a better understanding of the causes of certain 
diseases and the pathways involved in their progression. Optogenetic and chemogenetic 
techniques also provide huge potential for the research of neurological diseases, enabling the 
visualisation of neural networks and the design of receptors to regulate neuronal activity, 
respectively. The future of molecular neuroendocrinology will see a further expansion in 
knowledge with the aid of new technologies such as single molecule tracking to visualise the 
movement of proteins and the subsequent biological processes in living cells. With this more 
detailed understanding of the molecular basis of normal and abnormal function at the neuro-
hormonal interface, we expect to identify novel pathways as well as new therapeutic targets. 
This will ultimately lead to the development of new therapies to benefit patients with cancer 
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Figure 1: Genome Browser Shots showing GR binding sites (peaks) detected in regulatory 
elements of glucocorticoid-target genes in the rat hippocampus after acute stress (30min 
restraint) or exogenous corticosterone treatment (30min intravenous infusion).  Genome-
wide GR binding events were found to be highly similar between stress (red trace) and 
corticosterone treatment (blue trace) conditions. Peaks were detected at sites upstream, 
intronic and intergenic for genes encoding Period1 (a), Metallothionien1 / 2 (b), DNA damage 
inducible Transcript 4 (c), Camk2a (d), Bdnf (e), and Thra (f).  
Figure 2: Comparisons of sequencing techniques. a) ChIP-Seq reveals genome-wide 
interactions between proteins, such as hormone receptors, with specific DNA sequences. b) 
RNA-Seq is highly sensitive and enables analysis of gene expression across the genome. c) 
Protein sequencing can be performed using Liquid chromatography mass spectrometry (LC-
MS) to show protein expression, protein-protein interactions and post-translational 
modifications. d) DNase-Seq and ATAC-Seq map the more accessible, exposed, chromatin 
regions across the genome whereas FAIRE-Seq assesses proteins of the nucleosome depleted 
DNA. DNA regulatory areas where transcription factors bind and protect against enzyme 
digestion leave a footprint which can also be detected from DNase-Seq and ATAC-Seq data 
(63). e) MNase-Seq can be used to map where nucleosomes are present and therefore also 
where nucleosome free areas are found.  
Figure 3: Cellular distribution of mRNA for GR, MR and Per1 in the dentate gyrus of the rat 
hippocampus. RNA Fluorescent in situ hybridisation (RNAscope® Multiplex Fluorescent 
Reagent Kit v2 2.0; Advanced Cell Diagnostics Inc., Hayward, CA, US) was used to detect GR, 
MR and Per1 mRNA according to the manufacturer's protocol. Probes used were: GR Rn-
NR3C1, (catalog no. 466991), MR Rn-NR3C2 (custom designed probe targeting 1175-2062 of 
NM_013131.1; catalog no. 320269-C2) and Rn-Per1/466161(catalog no. 300031-C3), all from 
Advanced Cell Diagnostics Inc. The NR3C1 probe set was used in channel 1 with TSA Plus 
Fluorescein (NEL741001KT PerkinElmer). The NR3C2 probe set was used in channel 2 with TSA 
Plus Cyanine 3 (NEL744001KT PerkinElmer). The Per1 probe set was used in channel 3 with 
TSA Plus Cyanine 5 (NEL745001KT PerkinElmer). Fluorescent microscopy was performed on 
Leica SPE single channel confocal laser scanning microscope system at 40x magnification. 
Solid state lasers: 405nm (25mW), 488nm (10 mW), 532nm (10mW) and 635nm (18mW) were 
used to detect Dapi, Fluorescein, Cyanine 3 and Cyanine 5 respectively. Images were captured 
on a Leica DFC365FX monochrome digital camera (1392x1040 6.45μm pixels, 8 or 12 bit, 21 
fps full frame). 
Figure 4: Fos immunoreactivity (Fos-ir) in SON and PVN mCherry positive (hM3Dq-mCherry) 
vasopressin (AVP) neurons a) This illustrates the DREADD technique used in this study. b) 
Images showing Fos induction following 90min intraperitoneal administration of CNO 
targeting hM3Dq-mCherry expressing AVP neurons of the SON and PVN (90). Scale bars 
indicate 200μm; OT, optic tract; 3rd V, third ventricle. 
 
 
 
